<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Angela Dispenzieri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            S Vincent Rajkumar, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rebecca F Connor, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 14, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1378183">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of subunits of a variety of normal serum proteins. These fibrils have a predominantly antiparallel beta-pleated sheet configuration (noted on x-ray diffraction), and can be identified on biopsy specimens both by their characteristic appearance on electron microscopy and by their ability to bind Congo red (leading to green birefringence under polarized light) and thioflavine T (producing an intense yellow-green fluorescence).
        </p>
        <p>
         More than 30 distinct low molecular weight proteins are recognized to form amyloid fibrils. The four most common causes of systemic amyloid deposition are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin light chain (AL) amyloidosis (historically referred to as primary amyloidosis) in which the fibrils are composed of fragments of monoclonal light chains. Affected patients may have amyloidosis alone or in association with other plasma cell dyscrasias (multiple myeloma, Waldenström macroglobulinemia). All forms of systemic amyloidosis in which the fibrils are derived from monoclonal light chains, regardless of the nature of the underlying plasma cell disorder (eg, monoclonal gammopathy of undetermined significance, multiple myeloma, or Waldenström macroglobulinemia) are considered AL amyloidosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wild type transthyretin amyloidosis (ATTRwt, historically referred to as age-related [senile] amyloidosis) typically involves the heart and causes a restrictive cardiomyopathy. It is caused by deposition of normal unmutated transthyretin (TTR), which appears to be an inherently amyloidogenic protein. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Wild-type transthyretin systemic amyloidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary (familial) amyloidosis (ATTRmt) are the result of mutations in genes coding for several different proteins that are normally present in the body. The most common "amyloidogenic proteins" implicated in hereditary amyloidosis are mutated forms of TTR, the alpha chain of fibrinogen A, apolipoprotein AI and AII, lysozyme, and gelsolin. (See
         <a class="medical medical_review" href="/z/d/html/5590.html" rel="external">
          "Genetic factors in the amyloid diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AA amyloidosis in which the fibrils are composed of fragments of the acute phase reactant serum amyloid A. AA amyloidosis is typically reactive (secondary) to chronic inflammation. (See
         <a class="medical medical_review" href="/z/d/html/5619.html" rel="external">
          "Pathogenesis of AA amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Because AL amyloidosis is a clonal plasma cell disorder, it is treated with chemotherapy to eradicate the underlying clone. AL amyloidosis must be differentiated from other forms of amyloidosis (eg, AA amyloidosis, ATTRmt amyloidosis, and ATTRwt amyloidosis) since the latter are non-neoplastic and will not benefit from chemotherapy.
        </p>
        <p>
         AL amyloidosis is a systemic disorder that can present with a variety of symptoms or signs, including heavy proteinuria (usually in the nephrotic range), edema, hepatosplenomegaly, otherwise unexplained heart failure, and the carpal tunnel syndrome. Although virtually all patients have multisystem amyloid deposition, it is not uncommon to present with evidence of mainly one organ being affected. (See
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2642.html" rel="external">
          "Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122846.html" rel="external">
          "Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         The clinical presentation, diagnosis, and differential diagnosis of AL amyloidosis will be discussed here. An overview of the amyloid disorders as well as the pathogenesis, prognosis, and treatment of AL amyloidosis are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6665.html" rel="external">
          "Monoclonal immunoglobulin deposition disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6666.html" rel="external">
          "Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H143697">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         AL amyloidosis is an uncommon disorder and the exact incidence is unknown. In the United States, the incidence appears to be stable at approximately 9 to 14 cases per million person-years [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         AL amyloidosis is a disease of older adults. As with other plasma cell dyscrasias, the age-specific incidence rates increase in each decade of life after age 40 years [
         <a href="#rid1">
          1
         </a>
         ]. The median age at diagnosis is 64 years, and less than 5 percent of patients are under the age of 40 [
         <a href="#rid4">
          4-8
         </a>
         ]. There is a male predominance with men accounting for 65 to 70 percent of patients.
        </p>
        <p>
         AL amyloidosis occurs in all races and all geographic locations; however, there are few data regarding whether the incidence varies by ethnicity or geography.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Relation to other plasma cell disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients who ultimately show clinical evidence of AL amyloidosis present with what appeared to be monoclonal gammopathy of undetermined significance (MGUS). Once a diagnosis of AL amyloidosis is made, such patients are no longer considered to have MGUS. Over time, a small number of patients with MGUS eventually develop symptoms or signs of AL amyloidosis, multiple myeloma (MM), or Waldenström macroglobulinemia (WM), at a rate of approximately 1 percent per year [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">
          "Clinical course and management of monoclonal gammopathy of undetermined significance", section on 'Disease progression'
         </a>
         .)
        </p>
        <p>
         AL amyloidosis can also occur in patients with other plasma cell dyscrasias, including MM and WM, which are malignant disorders of plasma cells or lymphoplasmacytic cells, respectively. Less frequently, AL amyloidosis may be associated with marginal zone lymphoma or another non-Hodgkin lymphoma subtype [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         When MM and AL amyloidosis are diagnosed in the same patient, the myeloma is typically diagnosed before or around the time of the amyloidosis diagnosis. Less commonly, myeloma develops more than six months after the diagnosis of amyloidosis (delayed progression):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 1596 patients with AL amyloidosis seen at the Mayo Clinic between 1960 and 1994, only six (0.4 percent) showed delayed progression (at 10 to 81 months) to overt myeloma [
         <a href="#rid11">
          11
         </a>
         ]. This usually occurred in patients without cardiac or hepatic amyloidosis who lived long enough to develop myeloma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 4319 patients seen at the Mayo Clinic between 1990 and 2008 with a diagnosis of myeloma who had at least six months of follow-up, there were 47 patients (1.1 percent) in whom the diagnosis of AL amyloidosis followed the diagnosis of myeloma by at least six months [
         <a href="#rid12">
          12
         </a>
         ]. Outcome of these patients was poor, especially in those with cardiac involvement, with a median survival after the diagnosis of AL amyloidosis of nine months (95% CI 4-14 months).
        </p>
        <p>
        </p>
        <p>
         In patients with AL amyloidosis, hypercalcemia, bone pain, or lytic bone lesions is suggestive of the combination of clinical myeloma and amyloidosis. The diagnosis of coexisting MM is reserved for patients with amyloidosis who would otherwise meet diagnostic criteria for MM, usually with clonal bone marrow plasmacytosis ≥10 percent and one or more myeloma-defining events (MDEs) such as osteolytic bone lesions [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
         Although AL amyloidosis is not an MDE, outcomes of patients with AL amyloidosis who have clonal bone marrow plasmacytosis ≥10 percent are comparable to patients meeting criteria for coexisting MM due to the presence of MDEs [
         <a href="#rid14">
          14
         </a>
         ]. Therefore, such patients with AL amyloidosis without clinical myeloma who have a higher plasma cell burden (≥10 percent) should be managed more intensively than their low tumor burden counterparts. Although typical myeloma regimens are often not well tolerated in patients with AL amyloidosis, induction and maintenance strategies should be considered for those who meet the current criteria for coexistent myeloma.
        </p>
        <p class="headingAnchor" id="H143177">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H1664672">
         <span class="h2">
          Systemic presentations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation in AL amyloidosis depends on the number and nature of the organs affected. In some patients only one organ is affected, while in others there is extensive multi-system involvement. However, even in patients with more than one organ affected, it is usually possible to identify one organ as the "dominant" site of involvement. A more complete overview of the clinical manifestations of amyloidosis in general can be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Non-specific systemic symptoms, including fatigue and unintentional weight loss, are common in patients with AL amyloidosis [
         <a href="#rid15">
          15
         </a>
         ]. Other common clinical presentations of AL amyloidosis include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nephrotic syndrome
         </strong>
         – Renal involvement occurs in approximately 70 percent of patients and most often presents as asymptomatic proteinuria or clinically apparent nephrotic syndrome (50 percent). (See
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Restrictive cardiomyopathy
         </strong>
         – Cardiac involvement is seen in approximately 60 percent of patients and is typically characterized by thickening of the interventricular septum and ventricular wall  (
         <a class="graphic graphic_movie graphicRef64330" href="/z/d/graphic/64330.html" rel="external">
          movie 1
         </a>
         ). This can lead to systolic or diastolic dysfunction and the symptoms of heart failure. Other manifestations that can occur include sudden death or syncope due to arrhythmia or heart block, and rarely angina or infarction due to accumulation of amyloid in the coronary arteries. Elevations in N-terminal serum brain natriuretic peptide (BNP) in patients with AL amyloidosis are seen before the onset of clinical heart failure and are a marker of cardiac involvement. (See
         <a class="medical medical_review" href="/z/d/html/122846.html" rel="external">
          "Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral neuropathy
         </strong>
         – Mixed sensory and motor peripheral neuropathy (20 percent) and/or autonomic neuropathy (15 percent) is a prominent feature in AL amyloidosis. Symptoms of numbness, paresthesia, and pain are frequently noted, as in peripheral neuropathy of many other causes. Compression of peripheral nerves, especially the median nerve within the carpal tunnel, can cause more localized sensory changes. Symptoms of bowel or bladder dysfunction and findings of orthostatic hypotension may be due to autonomic nervous system damage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatomegaly, with elevated liver enzyme levels
         </strong>
         – Hepatomegaly with or without splenomegaly is seen in as many as 70 percent of patients. A cholestatic pattern with elevated liver enzymes is seen in approximately 25 percent. Clinical gastrointestinal involvement appears to be less common than in other forms of amyloidosis, with clinically apparent disease occurring in only 1 percent of patients [
         <a href="#rid16">
          16
         </a>
         ]. Because amyloidosis is a systemic disease, rates of positive gastrointestinal biopsies are much higher; in days past, rectal biopsy was considered a safe and simple method of diagnosing systemic amyloidosis with a sensitivity of 75 percent [
         <a href="#rid15">
          15
         </a>
         ]. For symptomatic patients potential gastrointestinal manifestations include bleeding (due to vascular fragility and loss of vasomotor responses to injury), gastroparesis, constipation, bacterial overgrowth, malabsorption, and intestinal pseudo-obstruction resulting from dysmotility. (See
         <a class="medical medical_review" href="/z/d/html/2642.html" rel="external">
          "Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Macroglossia and involvement of other muscles
         </strong>
         – Amyloid infiltration of skeletal muscles may cause visible enlargement (ie, pseudohypertrophy). A large tongue (ie, macroglossia), or lateral scalloping of the tongue from impingement on the teeth, is characteristic of AL amyloidosis  (
         <a class="graphic graphic_picture graphicRef79126" href="/z/d/graphic/79126.html" rel="external">
          picture 1
         </a>
         ). Arthropathy may be due to amyloid deposition in joints and surrounding structures. The "shoulder pad" sign is visible enlargement of the anterior shoulder due to fluid in the glenohumeral joint and/or amyloid infiltration of the synovial membrane and surrounding structures. (See
         <a class="medical medical_review" href="/z/d/html/5616.html" rel="external">
          "Musculoskeletal manifestations of amyloidosis", section on 'Muscle involvement in AL amyloid'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Purpura and other skin manifestations
         </strong>
         – Purpura, characteristically elicited in a periorbital distribution (raccoon eyes) by a Valsalva maneuver or minor trauma, is present in only a minority of patients, but is highly characteristic of AL amyloidosis  (
         <a class="graphic graphic_picture graphicRef51684" href="/z/d/graphic/51684.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. Other signs of skin involvement include waxy thickening, easy bruising (ecchymoses)  (
         <a class="graphic graphic_picture graphicRef69541" href="/z/d/graphic/69541.html" rel="external">
          picture 3
         </a>
         ), and subcutaneous nodules or plaques. Infiltration of the subcutaneous fat is generally asymptomatic but provides a convenient site for biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bleeding diathesis
         </strong>
         – Amyloidosis may be directly associated with a bleeding diathesis [
         <a href="#rid18">
          18-22
         </a>
         ]. In one report of 337 patients, abnormal bleeding and abnormal coagulation tests were seen in 28 and 51 percent, respectively [
         <a href="#rid19">
          19
         </a>
         ]. Proposed mechanisms include factor X deficiency due to binding to amyloid fibrils primarily in the liver and spleen; decreased synthesis of coagulation factors in patients with advanced liver disease; and acquired von Willebrand disease. However, some patients with abnormal bleeding have no abnormality in any coagulation test [
         <a href="#rid18">
          18
         </a>
         ]. In such patients, amyloid infiltration of blood vessels may contribute to the bleeding diathesis. (See
         <a class="medical medical_review" href="/z/d/html/110531.html" rel="external">
          "Acquired von Willebrand syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">
          "Pathophysiology of von Willebrand disease", section on 'Causes of reduced VWF in acquired VWS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Nearly 10 percent of patients will have clinical manifestations of coexisting MM characterized by anemia, hypercalcemia, and/or lytic bone lesions [
         <a href="#rid14">
          14
         </a>
         ]. Such patients may present with signs and symptoms related to the MM, such as bone pain and infection. (See
         <a class="local">
          'Relation to other plasma cell disorders'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1664740">
         <span class="h2">
          IgM-associated AL amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         AL amyloidosis is an uncommon complication of immunoglobulin M (IgM)-associated monoclonal gammopathies, such as Waldenström macroglobulinemia [
         <a href="#rid23">
          23-28
         </a>
         ]. IgM-related AL amyloidosis appears to be a distinct clinical entity with less cardiac involvement and a higher incidence of lymph node and soft tissue involvement (eg, liver damage, peripheral and autonomic neuropathy) when compared with non-IgM-related AL amyloidosis. (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Amyloidosis'
         </a>
         .)
        </p>
        <p>
         In the largest retrospective study, 131 of 250 patients with IgM-associated systemic AL amyloidosis had a clearly identified lymphoproliferative disorder, 39 of which predated the amyloidosis diagnosis [
         <a href="#rid27">
          27
         </a>
         ]. The most common identified conditions were lymphoplasmacytic lymphoma and non-Hodgkin lymphoma, not specifically classified. Rare cases of associated chronic lymphocytic leukemia and follicular lymphoma were seen. The involved light chain was kappa in 40 percent. The most commonly involved organs were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney (68 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Soft tissue (35 percent, including lymph nodes in 20 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver (17 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral nervous system (15 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autonomic nervous system (13 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal system (9 percent)
        </p>
        <p>
        </p>
        <p>
         On multivariate analysis, adverse prognostic features included older age, high NT-proBNP, elevated troponin T, liver involvement, and the presence of neuropathy. These features were combined into a novel prognostic score.
        </p>
        <p class="headingAnchor" id="H7747821">
         <span class="h2">
          IgD-associated AL amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is extremely rare for patients with AL amyloidosis to have a monoclonal immunoglobulin D (IgD) at the time of diagnosis. The largest single center retrospective case series of 3955 patients with Ig light chain amyloidosis identified 53 patients (1.3 percent) with a serum IgD monoclonal protein [
         <a href="#rid29">
          29
         </a>
         ]. When compared with non-IgD AL amyloidosis, patients appeared to have a lower frequency of renal and cardiac involvement. At the time of presentation, the most common signs and symptoms were fatigue (60 percent), lower extremity edema (43 percent), paresthesias (32 percent), weight loss (32 percent), dyspnea on exertion (28 percent), and carpal tunnel syndrome (26 percent). Survival appeared similar to that of non-IgD AL amyloidosis.
        </p>
        <p class="headingAnchor" id="H1664856">
         <span class="h1">
          PATHOLOGIC FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H1665772">
         <span class="h2">
          Tissue biopsy
         </span>
        </p>
        <p class="headingAnchor" id="H1666048">
         <span class="h3">
          Choosing a biopsy site
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of AL amyloidosis requires the demonstration of amyloid fibrils upon histologic evaluation of an affected organ (eg, kidney, liver) or a surrogate site (eg, abdominal fat pad, bone marrow). We suggest initial evaluation with an abdominal fat pad aspirate and bone marrow biopsy because of their ease, convenience, and high yield  (
         <a class="graphic graphic_algorithm graphicRef131750" href="/z/d/graphic/131750.html" rel="external">
          algorithm 1
         </a>
         ). Either or both are positive in 90 percent of patients with AL amyloidosis. If AL amyloidosis is still suspected in the setting of negative fat pad aspirate and bone marrow biopsy, then the affected organ should be biopsied.
        </p>
        <p>
         The choice of initial biopsy site must take into consideration the expected yield, accessibility of the site, and the risks associated with the procedure. Kidney or liver biopsy is positive in over 90 percent of cases; however, a high success rate can also be achieved by less invasive procedures, such as abdominal fat pad aspirate (60 to 80 percent), rectal biopsy (50 to 70 percent), bone marrow biopsy (50 to 55 percent), or skin biopsy (50 percent) [
         <a href="#rid15">
          15,30-33
         </a>
         ].
        </p>
        <p>
         We do not perform gingival biopsy because it is uncomfortable for the patient, and skin biopsies are generally negative unless there is clinical involvement or if a considerable amount of fat is taken with the skin. In addition, some patients have a bleeding diathesis (eg, acquired factor X deficiency), which may limit the safety of biopsy of major internal organs. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Hematologic abnormalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1666055">
         <span class="h3">
          Identifying amyloid
         </span>
         <span class="headingEndMark">
          —
         </span>
         On hematoxylin- and eosin-stained biopsy sections, amyloid appears as a pink, amorphous, waxy substance with a characteristic 'cracking' artifact  (
         <a class="graphic graphic_picture graphicRef63840" href="/z/d/graphic/63840.html" rel="external">
          picture 4
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ]. The presence of amyloid fibrils can be confirmed by their characteristic appearance on electron microscopy  (
         <a class="graphic graphic_picture graphicRef54148" href="/z/d/graphic/54148.html" rel="external">
          picture 5
         </a>
         ) and by their ability to bind Congo red (leading to green birefringence under polarized light)  (
         <a class="graphic graphic_picture graphicRef78183 graphicRef56789" href="/z/d/graphic/78183.html" rel="external">
          picture 6A-B
         </a>
         ) or thioflavine-T (producing an intense yellow-green fluorescence) [
         <a href="#rid35">
          35
         </a>
         ]. The estimated sensitivity and specificity of Congo red staining on light microscopy for amyloid are 79 and 80 percent, respectively [
         <a href="#rid36">
          36
         </a>
         ]. The sensitivity for kappa (74 percent) is lower than that for lambda (84 percent). Of importance, biopsy sections that are very thin (ie, 6 microns or less) may not stain appropriately with Congo red despite the presence of amyloid fibrils on electron microscopy.
        </p>
        <p class="headingAnchor" id="H1666063">
         <span class="h3">
          Determining the type of amyloid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the histologic diagnosis of amyloid is made (typically based on the Congo red stain), there are a number of laboratory and histologic findings that may distinguish AL amyloidosis from other forms of amyloidosis on tissue specimens. Mass spectrometry is the preferred method since immunohistochemistry and immunofluorescence have a greater risk of false positive and false negative results. However, this test is not widely available, and appropriate tissue samples need to be sent to referral centers for such testing. If available, immunoelectron microscopy is an acceptable alternative to mass spectrometry.
        </p>
        <p>
         The following describes the use of each of these methods:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laser microdissection with mass spectrometry (MS) combines tissue sampling by laser microdissection along with tandem mass spectrometry-based proteomic analysis [
         <a href="#rid37">
          37-40
         </a>
         ]. This technique is able to efficiently and accurately identify all types of amyloid, including rare subtypes, with 100 percent specificity [
         <a href="#rid8">
          8
         </a>
         ]. In a study of 50 cases of amyloidosis well-characterized by gold standard clinicopathologic criteria (training set) and an independent validation set comprising 41 cases of cardiac amyloidosis, this technique identified the amyloid type with 100 percent specificity and sensitivity in the training set and 98 percent in the validation set [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunohistochemical staining (eg, for kappa and lambda light chains, transthyretin, and serum amyloid A component) of the amyloid can determine the type of amyloidosis [
         <a href="#rid41">
          41
         </a>
         ]. Positive staining for kappa or lambda indicates AL amyloidosis; positive staining for transthyretin indicates hereditary or wild type transthyretin (ATTRmt or ATTRwt) amyloidosis; positive staining for serum amyloid A component occurs with secondary (AA) amyloidosis. However, immunohistochemical staining should only be done at centers with considerable expertise with the antibodies since false negatives and false positives are common in inexperienced hands.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoelectron microscopy combines immunohistochemistry and electron microscopy to confirm amyloid deposition and identify the protein within the amyloid fibrils. In one study, when compared with Congo red staining, immunoelectron microscopy had similar sensitivity (76 percent) and higher specificity (100 percent) for amyloid [
         <a href="#rid36">
          36
         </a>
         ]. The sensitivity for kappa (71 percent) was lower than for lambda (83 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunofluorescence microscopy in the kidney or other affected tissue  (
         <a class="graphic graphic_picture graphicRef79371" href="/z/d/graphic/79371.html" rel="external">
          picture 7
         </a>
         ) may show deposition of a monoclonal (lambda or kappa) light chain in AL amyloidosis, although some have reported a low sensitivity with renal biopsies (65 percent in one series) [
         <a href="#rid42">
          42
         </a>
         ]. Immunofluorescence using light-chain specific antisera and other specialized techniques can also be used with other tissue specimens to help diagnose AL amyloidosis  (
         <a class="graphic graphic_picture graphicRef73654" href="/z/d/graphic/73654.html" rel="external">
          picture 8
         </a>
         ) [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1666444">
         <span class="h3">
          Chromosomal changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with AL amyloidosis frequently have chromosomal abnormalities, but there is no single chromosomal change that is diagnostic of this disease. The monotypic plasma cell population in the bone marrow has elements of a neoplastic nature as shown by the frequent finding of numerical chromosomal abnormalities. In a study of bone marrow samples with fluorescence in situ hybridization (FISH) from 21 patients with AL amyloidosis, monosomy of chromosome 18 was the most common abnormality, occurring in 72 percent of cases, but trisomy of a variety of chromosomes was also common [
         <a href="#rid45">
          45
         </a>
         ]. Similar prevalences were found in 19 patients with monoclonal gammopathy of undetermined significance (MGUS). (See
         <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">
          "Diagnosis of monoclonal gammopathy of undetermined significance"
         </a>
         .)
        </p>
        <p>
         When a myeloma FISH panel is applied to patients with AL amyloidosis, t(11;14)(q13;q32) is the most common abnormality, seen in nearly 50 percent of patients; other commonly seen abnormalities include del(13q14) and gain of 1q21 [
         <a href="#rid46">
          46-50
         </a>
         ]. High-risk FISH abnormalities (eg, 17p13 deletion) are distinctively uncommon. (See
         <a class="medical medical_review" href="/z/d/html/6660.html" rel="external">
          "Multiple myeloma: Pathobiology", section on 'Cytogenetic abnormalities'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Cytogenetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1665099">
         <span class="h2">
          Evidence of monoclonal plasma cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of AL amyloidosis requires evidence of a monoclonal plasma cell proliferative disorder as displayed by the presence of a serum or urine monoclonal (M) protein, an abnormal serum free light chain ratio, or clonal plasma cells in the bone marrow.
        </p>
        <p>
         A monoclonal plasma cell proliferative disorder can be assumed if an M protein is detected in the serum or urine. The M protein in AL amyloidosis is IgG in approximately 35 percent, IgA in 10 percent, IgM in 5 percent, IgD in 1 percent, and light chain (lambda or kappa) in the remaining patients [
         <a href="#rid51">
          51
         </a>
         ]. Most patients with AL amyloidosis have little or no intact monoclonal immunoglobulin, but are characterized by the presence of monoclonal free light chain. The monoclonal light chain type is lambda in approximately 70 percent of cases, kappa in 25 percent, and biclonal in 5 percent [
         <a href="#rid52">
          52
         </a>
         ]. Evaluation with serum and urine immunofixation plus a serum free light chain ratio analysis provides the most sensitive measure for this M protein:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum protein electrophoresis (SPEP), which detects intact monoclonal immunoglobulin, will demonstrate a localized band or peak in less than 50 percent of patients with AL amyloidosis. (See
         <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">
          "Laboratory methods for analyzing monoclonal proteins", section on 'Serum protein electrophoresis (SPEP)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunofixation techniques designed to identify light chains will detect a serum or urinary M protein in nearly 90 percent of cases of AL amyloidosis [
         <a href="#rid7">
          7
         </a>
         ]. Of importance, a subset of patients has very small M protein levels that may only be detected by immunofixation (eg, monoclonal IgD) [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">
          "Laboratory methods for analyzing monoclonal proteins", section on 'Serum immunofixation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When serum and urine immunofixation is combined with serum free light chain ratio analysis, an M protein can be detected in virtually all cases [
         <a href="#rid7">
          7,52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">
          "Laboratory methods for analyzing monoclonal proteins", section on 'Serum free light chains'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Clonal plasma cells can also be identified in the bone marrow. Bone marrow biopsy specimens typically demonstrate a slightly increased percentage of plasma cells that may appear morphologically normal [
         <a href="#rid34">
          34
         </a>
         ]. Less commonly, the bone marrow demonstrates overt myeloma or lymphoplasmacytic lymphoma. A clonal excess of plasma cells (lambda or kappa) can also be demonstrated by immunoperoxidase staining or flow cytometric analysis of specimens of involved bone marrow  (
         <a class="graphic graphic_picture graphicRef79371" href="/z/d/graphic/79371.html" rel="external">
          picture 7
         </a>
         ) [
         <a href="#rid53">
          53,54
         </a>
         ]. However, a monoclonal plasma cell staining pattern typical of AL amyloidosis may be missed if the clone is small and masked by normal polyclonal plasma cells.
        </p>
        <p class="headingAnchor" id="H1666806">
         <span class="h1">
          IMAGING
         </span>
        </p>
        <p class="headingAnchor" id="H1666860">
         <span class="h2">
          Serum amyloid P component scintigraphy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum amyloid P component (SAP) scintigraphy is a method of measuring the extent of amyloid involvement by using a radiolabeled variant of the SAP found in all amyloid deposits [
         <a href="#rid55">
          55,56
         </a>
         ]. Tissue amyloid deposits are identified by scintigraphy following the intravenous injection of technetium-labeled SAP [
         <a href="#rid57">
          57,58
         </a>
         ]. This test is more accurate in secondary amyloidosis [
         <a href="#rid59">
          59
         </a>
         ] and may be positive even when tissue biopsy has been negative [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         The value of SAP scintigraphy is limited because it is inconvenient, costly, not widely available, and is less helpful in detecting cardiac amyloidosis. Another limitation is that the SAP is currently obtained from blood donors, thereby carrying a potential infectious risk.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         AL amyloidosis is suspected in a patient presenting with any one of the following  (
         <a class="graphic graphic_algorithm graphicRef131750" href="/z/d/graphic/131750.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-diabetic nephrotic range proteinuria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restrictive cardiomyopathy or otherwise unexplained congestive heart failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased NT-proBNP in the absence of known primary heart disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained edema, hepatosplenomegaly, or carpal tunnel syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained facial or neck purpura
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macroglossia
        </p>
        <p>
        </p>
        <p>
         The initial evaluation of a patient suspected of having AL amyloidosis should consist of serum and urine protein electrophoresis with immunofixation, serum free light chain ratio analysis, and an abdominal fat pad aspirate and bone marrow biopsy [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="local">
          'Choosing a biopsy site'
         </a>
         above.)
        </p>
        <p>
         If AL amyloidosis is still suspected in the setting of negative fat pad aspirate and bone marrow biopsy, then the affected organ (eg, kidney, liver) should be biopsied. Some patients have a bleeding diathesis, which may limit the safety of biopsy of major internal organs. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Hematologic abnormalities'
         </a>
         .)
        </p>
        <p>
         The following tests are performed to assess for clinical organ involvement:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney – 24-hour urine for protein electrophoresis, creatinine, estimated glomerular filtration rate, and serum albumin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart – Troponin T, NT-proBNP, echocardiography, and electrocardiogram.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver – Alkaline phosphatase; if involvement is suspected clinically, ultrasound or computed tomography to assess liver size.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coagulation system – Factor X levels; alternatively, clinicians may choose to check prothrombin time (PT) and partial thromboplastin time (PTT) with plans to check factor X levels in patients with abnormal bleeding or abnormal testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuropathy – Patients with neurologic symptoms should be evaluated with electromyography (EMG) and nerve conduction studies. Since the neuropathy is most typically a small fiber neuropathy, these tests are often normal despite patient’s complaint of paresthesia or dysesthesia.
        </p>
        <p>
        </p>
        <p>
         Additional testing is performed after diagnosis as part of the pretreatment evaluation. This described in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6666.html" rel="external">
          "Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic criteria for AL amyloidosis have been developed by the Mayo Clinic and the International Myeloma Working Group and require the presence of
         <strong>
          all
         </strong>
         of the following four criteria  (
         <a class="graphic graphic_table graphicRef116385" href="/z/d/graphic/116385.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid13">
          13,61,62
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of an amyloid-related systemic syndrome (eg, renal, liver, heart, gastrointestinal tract or peripheral nerve involvement). In order to be included as a diagnostic criterion, the organ damage must be felt to be related to amyloid deposition and not to another common disease, such as diabetes or hypertension. (See
         <a class="local">
          'Systemic presentations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Positive amyloid staining by Congo red in any tissue (eg, fat aspirate, bone marrow or organ biopsy) or the presence of amyloid fibrils on electron microscopy. (See
         <a class="local">
          'Identifying amyloid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence that the amyloid is light chain-related established by direct examination of the amyloid using spectrometry-based proteomic analysis or immunoelectron microscopy. (See
         <a class="local">
          'Determining the type of amyloid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of a monoclonal plasma cell proliferative disorder (eg, presence of a serum or urine M protein, abnormal serum free light chain ratio, or clonal plasma cells in the bone marrow). (See
         <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">
          "Laboratory methods for analyzing monoclonal proteins", section on 'Serum free light chains'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Approximately 2 to 3 percent of patients with AL amyloidosis will
         <strong>
          not
         </strong>
         meet the requirement for evidence of a monoclonal plasma cell disorder listed above; the diagnosis of AL amyloidosis must be made with caution in these patients.
        </p>
        <p>
         Given the common occurrence of monoclonal gammopathy of undetermined significance (MGUS) in the general population, especially in the elderly, the presence of a monoclonal protein in conjunction with the demonstration of amyloid deposition may not always indicate that the amyloidosis is of the AL type. As an example, a patient may have wild type transthyretin amyloidosis and a concomitant unrelated MGUS, which can be potentially misdiagnosed as AL amyloidosis. As such, the amyloid itself should be examined directly for light chains rather than assuming a diagnosis of AL amyloidosis based on the presence of monoclonal light chains in the serum of a patient with amyloidosis. (See
         <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">
          "Diagnosis of monoclonal gammopathy of undetermined significance"
         </a>
         .)
        </p>
        <p>
         Patients with AL amyloidosis who have hypercalcemia, bone pain, or lytic bone lesions should be evaluated for coexisting multiple myeloma. (See
         <a class="local">
          'Relation to other plasma cell disorders'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         AL amyloidosis should be distinguished from other forms of amyloidosis, from localized amyloidosis, and from other types of monoclonal immunoglobulin deposition diseases, because the clinical course and therapy are markedly different.
        </p>
        <p class="headingAnchor" id="H58766172">
         <span class="h2">
          Other forms of amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other forms of amyloidosis include wild type transthyretin amyloidosis, hereditary amyloidosis, and AA amyloidosis. All of these entities will demonstrate staining with Congo red (a characteristic of amyloid), but direct examination of the amyloid material will not reveal immunoglobulin light chains (as seen in AL amyloidosis). A diagnosis of AL amyloidosis cannot be assumed based on the presence of monoclonal light chains in the serum of a patient with amyloid since it is not uncommon for a patient with another form of amyloid to have a concomitant and unrelated monoclonal gammopathy of undetermined significance (MGUS).
        </p>
        <p class="headingAnchor" id="H793556525">
         <span class="h3">
          ATTRwt amyloidosis (age-related amyloidosis)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wild type transthyretin amyloidosis (ATTRwt) refers to the deposition of otherwise normal (wild-type) transthyretin (TTR) in the myocardium and other sites of older adults [
         <a href="#rid63">
          63,64
         </a>
         ]. ATTRwt has historically been referred to as age-related or senile amyloidosis. Patients may present with heart failure or an arrhythmia. Recognition is important because survival is better than with AL amyloidosis, and chemotherapy or hematopoietic cell transplantation are contraindicated. Unlike AL amyloidosis, direct examination of the amyloid material in ATTRwt does not reveal immunoglobulin light chains, but rather reveals TTR deposits. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Wild-type transthyretin systemic amyloidosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H58766300">
         <span class="h3">
          Hereditary (familial) amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heritable, autosomal dominant amyloidosis results from mutations in genes coding for several different proteins. The most common "amyloidogenic proteins" implicated in hereditary amyloidosis are mutated forms of transthyretin (TTR), the alpha chain of fibrinogen A, apolipoprotein AI and AII, lysozyme, and gelsolin. Hereditary systemic AL amyloidosis not due to a plasma cell dyscrasia has been described in one family [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Sporadic cases of hereditary amyloidosis may be confused with AL amyloidosis, and diagnosis requires careful assessment to determine the chemical nature of the amyloid deposits by mass spectroscopy. The frequency with which this might occur was illustrated in a study of 350 patients suspected of having AL amyloidosis by clinical and laboratory findings and the absence of a family history; 34 (9.7 percent) had a mutant gene for an "amyloidogenic" protein, most often involving the alpha chain of fibrinogen A or transthyretin [
         <a href="#rid66">
          66
         </a>
         ]. The presence of low concentrations of monoclonal immunoglobulins (less than 0.2 g/dL) in 8 of these 34 patients may have contributed to the misdiagnosis. (See
         <a class="medical medical_review" href="/z/d/html/5590.html" rel="external">
          "Genetic factors in the amyloid diseases"
         </a>
         .)
        </p>
        <p>
         A thorough family history and exclusion of these heritable disorders is important, since the treatment used in AL amyloidosis (eg, chemotherapy, hematopoietic cell transplantation) has no role in the treatment of the hereditary amyloidoses, and is dangerous. Unlike AL amyloidosis, direct examination of the amyloid material in hereditary amyloidosis does not reveal immunoglobulin light chains. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2292467425">
         <span class="h3">
          AA amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         AA amyloidosis (previously referred to as secondary amyloidosis) occurs as a complication of a variety of chronic inflammatory conditions, such as rheumatoid arthritis and its variants, bronchiectasis, Crohn's disease and other inflammatory bowel diseases, osteomyelitis, and familial Mediterranean fever. Inflammation leads to increased hepatic production of the acute phase reactant serum amyloid A, which is then degraded in circulating macrophages into smaller amyloid A fragments that are then deposited as fibrils in the tissues. A distinction between AA amyloidosis and AL amyloidosis can be made based on the identification of immunoglobulin light chains upon the direct examination of the amyloid material in AL amyloidosis, a feature that is not seen in secondary amyloidosis. (See
         <a class="medical medical_review" href="/z/d/html/5619.html" rel="external">
          "Pathogenesis of AA amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5602.html" rel="external">
          "Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases"
         </a>
         .)
        </p>
        <p>
         A diagnosis of AL amyloidosis cannot be assumed based on the presence of monoclonal light chains in the serum of a patient with amyloid since it is not uncommon for a patient with other forms of amyloidosis to have a concomitant and unrelated MGUS.
        </p>
        <p class="headingAnchor" id="H3901681594">
         <span class="h2">
          Localized amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Localized amyloidosis is the term used for local amyloid deposits in tissues such as the tracheobronchial tree, urinary tract, or skin; these deposits are derived from monoclonal light chains, but are not due to an underlying
         <strong>
          systemic
         </strong>
         clonal plasma cell disorder. Patients with localized amyloidosis do not develop systemic disease (ie, cardiac, renal, hepatic, or nerve involvement) and do not require chemotherapy [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Localized AL amyloidosis is most commonly found in the upper respiratory tract (nasopharynx), urinary bladder, colon, skin and nails, and orbit [
         <a href="#rid68">
          68-74
         </a>
         ]. In most of these patients, monoclonal immunoglobulins cannot be found in serum or urine, although the amyloid fibrils are usually light chain-derived. These light chains are usually derived from more than one light chain variable family and may not be clonal [
         <a href="#rid8">
          8
         </a>
         ]. While damage to the affected site may occur (eg, nasal or colonic bleeding, tracheobronchial obstruction, hematuria), the clinical course is usually benign and surgical excision may be the only treatment needed [
         <a href="#rid70">
          70,75,76
         </a>
         ]. If there is evidence of a circulating monoclonal protein in patients with localized amyloidosis, it is important to confirm the absence of systemic AL amyloidosis with an investigation for sites of additional disease (ie, liver function tests, 24-hour urine protein, serum creatinine and echocardiography) to ensure appropriate management. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H58766423">
         <span class="h2">
          Other forms of systemic monoclonal immunoglobulin deposition disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The monoclonal immunoglobulin deposition diseases (MIDD) are a group of disorders characterized by the accumulation of intact or fragmented abnormal immunoglobulin in visceral and soft tissues resulting in organ damage. The MIDD are plasma cell dyscrasias with abnormal immunoglobulin components secreted by plasma cells or a lymphoplasmacytic neoplasm. There are four major groups of MIDD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AL amyloidosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Light chain deposition disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Light and heavy chain deposition disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heavy chain deposition disease
        </p>
        <p>
        </p>
        <p>
         All of these entities will have evidence of a monoclonal plasma cell proliferative disorder and many will demonstrate light chains in the serum. However, only AL amyloidosis will demonstrate staining with Congo red.
        </p>
        <p class="headingAnchor" id="H1662053">
         <span class="h3">
          Light chain deposition disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Light chain deposition disease (LCDD) is a monoclonal immunoglobulin deposition disease related to AL amyloidosis in which fibril formation does not occur, but fragments of monoclonal light chains are deposited in the tissues [
         <a href="#rid4">
          4,35
         </a>
         ]. LCDD typically presents as nephrotic syndrome and/or renal insufficiency [
         <a href="#rid77">
          77
         </a>
         ]. Most patients with renal involvement progress to end-stage kidney disease requiring dialysis [
         <a href="#rid78">
          78-80
         </a>
         ]. Less frequently, liver involvement can occur with hepatomegaly and liver dysfunction, either alone or in combination with renal involvement. Rarely, LCDD may involve the heart and lead to cardiomyopathy and heart failure or involve the peripheral nerves, salivary glands, gastrointestinal tract, and/or skin. Patients may progress to overt multiple myeloma; some patients may have coexisting multiple myeloma at initial diagnosis. Unlike AL amyloidosis, LCDD does not stain with Congo red. (See
         <a class="medical medical_review" href="/z/d/html/6665.html" rel="external">
          "Monoclonal immunoglobulin deposition disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1662108">
         <span class="h3">
          Heavy chain deposition disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heavy chain deposition disease (HCDD) is a rare monoclonal immunoglobulin deposition disease that has clinical characteristics that are similar to AL amyloidosis and LCDD. Deposits in HCDD are heavy chains or short (truncated) heavy chains, granular, and do not stain positive with Congo red. (See
         <a class="medical medical_review" href="/z/d/html/6665.html" rel="external">
          "Monoclonal immunoglobulin deposition disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H239299806">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119668.html" rel="external">
          "Society guideline links: Immunoglobulin light chain (AL) amyloidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1423758167">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/116276.html" rel="external">
          "Patient education: AL amyloidosis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relation to other plasma cell disorders
         </strong>
         – Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of subunits of a variety of normal serum proteins. AL amyloidosis (previously called primary amyloidosis) is a clonal plasma cell proliferative disorder in which fibrils of monoclonal light chains are deposited in the kidneys, heart, and other tissues. Affected patients may have AL amyloidosis alone or in association with other plasma cell dyscrasias (multiple myeloma, Waldenström macroglobulinemia). (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – The clinical presentation in AL amyloidosis depends on the number and nature of the organs affected. Non-specific systemic symptoms, including fatigue and unintentional weight loss, are common. Other common clinical presentations include nephrotic syndrome, restrictive cardiomyopathy, peripheral neuropathy, and hepatomegaly with elevated liver enzymes. Other less common but suggestive signs are macroglossia, purpura, and an unexplained bleeding diathesis. (See
         <a class="local">
          'Systemic presentations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tissue biopsy
         </strong>
         – The diagnosis of AL amyloidosis requires a biopsy. An abdominal fat pad aspirate and bone marrow biopsy are the preferred sites to biopsy in patients with suspected AL amyloidosis due to the ease of access and safety of accessing these sites  (
         <a class="graphic graphic_algorithm graphicRef131750" href="/z/d/graphic/131750.html" rel="external">
          algorithm 1
         </a>
         ). Either or both are positive in 90 percent of patients with AL amyloidosis. (See
         <a class="local">
          'Tissue biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic criteria
         </strong>
         – Diagnostic criteria for systemic AL amyloidosis require the presence of
         <strong>
          all
         </strong>
         of the following  (
         <a class="graphic graphic_table graphicRef116385" href="/z/d/graphic/116385.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Diagnostic criteria'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of an amyloid-related systemic syndrome (eg, renal, liver, heart, gastrointestinal tract or peripheral nerve involvement). (See
         <a class="local">
          'Systemic presentations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive amyloid staining by Congo red in any tissue (eg, fat aspirate, bone marrow or organ biopsy). (See
         <a class="local">
          'Identifying amyloid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evidence that the amyloid is light chain-related established by direct examination of the amyloid (eg, using mass spectrometry based proteomic analysis; note that immunohistochemistry results to type amyloid may be unreliable). (See
         <a class="local">
          'Determining the type of amyloid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evidence of a monoclonal plasma cell proliferative disorder (eg, presence of a serum or urine M protein, abnormal serum free light chain ratio, or clonal plasma cells in the bone marrow). (See
         <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">
          "Laboratory methods for analyzing monoclonal proteins", section on 'Serum free light chains'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – AL amyloidosis should be distinguished from other forms of amyloidosis, from localized amyloidosis, and from other types of monoclonal immunoglobulin deposition diseases (MIDD) because the clinical course and therapy are markedly different.
        </p>
        <p class="bulletIndent1">
         <br/>
         Other forms of amyloidosis will demonstrate staining with Congo red (a characteristic of amyloid), but direct examination of the amyloid material will not reveal immunoglobulin light chains (as seen in AL amyloidosis). (See
         <a class="local">
          'Other forms of amyloidosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other forms of MIDD will have evidence of a monoclonal plasma cell proliferative disorder and many will demonstrate light chains in the serum. However, AL amyloidosis is the only MIDD that will demonstrate staining with Congo red. (See
         <a class="local">
          'Other forms of systemic monoclonal immunoglobulin deposition disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H359636812">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert A Kyle, MD, who contributed as a Section Editor to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79:1817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2018; 2:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Larson DR, Kurtin PJ, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 2019; 94:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimazaki C, Hata H, Iida S, et al. Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan. Intern Med 2018; 57:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muchtar E, Gertz MA, Kyle RA, et al. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. Mayo Clin Proc 2019; 94:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasari S, Theis JD, Vrana JA, et al. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clin Proc 2020; 95:1852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basset M, Defrancesco I, Milani P, et al. Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. Blood 2020; 135:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998; 82:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010; 85:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013; 31:4319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menke DM, Kyle RA, Fleming CR, et al. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc 1993; 68:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eder L, Bitterman H. Image in clinical medicine. Amyloid purpura. N Engl J Med 2007; 356:2406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yood RA, Skinner M, Rubinow A, et al. Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983; 249:1322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sucker C, Hetzel GR, Grabensee B, et al. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006; 47:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greipp PR, Kyle RA, Bowie EJ. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med 1979; 301:1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greipp PR, Kyle RA, Bowie EJ. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol 1981; 11:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin Oncol 1993; 11:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertz MA, Kyle RA. Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 2003; 30:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008; 87:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wechalekar AD, Lachmann HJ, Goodman HJ, et al. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008; 112:4009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sachchithanantham S, Roussel M, Palladini G, et al. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. J Clin Oncol 2016; 34:2037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sissoko M, Sanchorawala V, Seldin D, et al. Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid 2015; 22:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertz MA, Buadi FK, Hayman SR, et al. Immunoglobulin D amyloidosis: a distinct entity. Blood 2012; 119:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience. Am J Med 1987; 82:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duston MA, Skinner M, Meenan RF, Cohen AS. Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum 1989; 32:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sungur C, Sungur A, Ruacan S, et al. Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever. Kidney Int 1993; 44:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia Y, Collins AB, Stone JR. Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis. Hum Pathol 2018; 72:71.
          </a>
         </li>
         <li class="breakAll">
          World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med 1980; 302:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández de Larrea C, Verga L, Morbini P, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood 2015; 125:2239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114:4957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5:2180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119:1844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012; 119:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novak L, Cook WJ, Herrera GA, Sanders PW. AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transplant 2004; 19:3050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anesi E, Palladini G, Perfetti V, et al. Therapeutic advances demand accurate typing of amyloid deposits. Am J Med 2001; 111:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrera GA, Sanders PW, Reddy BV, et al. Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain-related renal diseases. Ultrastruct Pathol 1994; 18:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonseca R, Ahmann GJ, Jalal SM, et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol 1998; 103:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001; 98:2266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison CJ, Mazzullo H, Ross FM, et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 2002; 117:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bochtler T, Hegenbart U, Cremer FW, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008; 111:4700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryce AH, Ketterling RP, Gertz MA, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bochtler T, Merz M, Hielscher T, et al. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv 2018; 2:2607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paiva B, Vídriales MB, Pérez JJ, et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood 2011; 117:3613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muchtar E, Jevremovic D, Dispenzieri A, et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood 2017; 129:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990; 323:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallo G, Wisniewski T, Choi-Miura NH, et al. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkins PN, Pepys MB. Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med 1995; 22:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jager PL, Hazenberg BP, Franssen EJ, et al. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 1998; 39:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillmore JD, Wechalekar A, Bird J, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol 2015; 168:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016; 91:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertz MA, Kyle RA, Edwards WD. Recognition of congestive heart failure due to senile cardiac amyloidosis. Biomed Pharmacother 1989; 43:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benson MD, Liepnieks JJ, Kluve-Beckerman B. Hereditary systemic immunoglobulin light-chain amyloidosis. Blood 2015; 125:3281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346:1786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmood S, Bridoux F, Venner CP, et al. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematol 2015; 2:e241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guidelines Working Group of UK Myeloma Forum, British Commitee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita Y, Tsuji-Abe Y, Sato-Matsumura KC, et al. Nail dystrophy and blisters as sole manifestations in myeloma-associated amyloidosis. J Am Acad Dermatol 2006; 54:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A. Localized AL amyloidosis of the colon: an unrecognized entity. Amyloid 2003; 10:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tirzaman O, Wahner-Roedler DL, Malek RS, et al. Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000; 75:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kourelis TV, Kyle RA, Dingli D, et al. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. Mayo Clin Proc 2017; 92:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grogg KL, Aubry MC, Vrana JA, et al. Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder. Am J Surg Pathol 2013; 37:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basset M, Hummedah K, Kimmich C, et al. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. Am J Hematol 2020; 95:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domínguez S, Wienberg P, Clarós P, et al. Primary localized nasopharyngeal amyloidosis. A case report. Int J Pediatr Otorhinolaryngol 1996; 36:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiser R, Mikesch K, Fisch P, et al. Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol 2004; 125:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012; 7:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sayed RH, Wechalekar AD, Gilbertson JA, et al. Natural history and outcome of light chain deposition disease. Blood 2015; 126:2805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly F, Cohen C, Javaugue V, et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood 2019; 133:576.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6668 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1558973" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29748430" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Epidemiology of AL amyloidosis: a real-world study using US claims data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30713046" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6353084" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Amyloidosis (AL). Clinical and laboratory features in 229 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3719098" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29093404" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30770096" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32861330" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11856795" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31714952" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9554527" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Primary systemic amyloidosis with delayed progression to multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20194151" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25439696" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24145344" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7878478" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Primary systemic amyloidosis: clinical and laboratory features in 474 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8331978" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17554122" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Image in clinical medicine. Amyloid purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6600795" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bleeding manifestations in 100 patients with amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10971408" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16731289" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/492235" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Factor X deficiency in primary amyloidosis: resolution after splenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7036713" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Factor-X deficiency in amyloidosis: a critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8487054" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12720162" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Amyloidosis with IgM monoclonal gammopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344807" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18708629" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27114592" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26488936" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical presentation and treatment responses in IgM-related AL amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22065594" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Immunoglobulin D amyloidosis: a distinct entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2435149" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2912466" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7505040" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29133141" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29133141" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6154243" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25636337" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A practical approach to the diagnosis of systemic amyloidoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19797517" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876678" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20937937" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21917755" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22106346" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15507480" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : AL-amyloidosis is underdiagnosed in renal biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11545098" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Therapeutic advances demand accurate typing of amyloid deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7941038" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain-related renal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9858220" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Chromosomal abnormalities in systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568015" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11972529" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18305218" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19211640" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30327369" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9110907" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19131635" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21266717" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27729322" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2377176" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8080036" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Potential role of apolipoprotein-E in fibrillogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7498219" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Imaging amyloidosis with radiolabelled SAP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9544684" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7645531" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Treatment of amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25312307" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Guidelines on the diagnosis and investigation of AL amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18971951" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27291302" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2736272" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Recognition of congestive heart failure due to senile cardiac amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983293" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25858898" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hereditary systemic immunoglobulin light-chain amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050338" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26688234" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15180858" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Guidelines on the diagnosis and management of AL amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16546597" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Nail dystrophy and blisters as sole manifestations in myeloma-associated amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12762141" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Localized AL amyloidosis of the colon: an unrecognized entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11126834" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Primary localized amyloidosis of the urinary bladder: a case series of 31 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28483059" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23282974" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32602121" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8803693" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Primary localized nasopharyngeal amyloidosis. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15180856" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22156754" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14655186" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26392598" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Natural history and outcome of light chain deposition disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30578255" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
